Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
24.00
+0.58 (+2.48%)
Streaming Delayed Price
Updated: 12:31 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veracyte Inc
< Previous
1
2
3
4
5
6
Next >
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 03, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
May 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 16, 2022
From
Veracyte, Inc.
Via
Business Wire
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
May 12, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
May 12, 2022
From
Veracyte
Via
Business Wire
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
May 04, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces First Quarter 2022 Financial Results
May 03, 2022
From
Veracyte, Inc.
Via
Business Wire
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
May 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
April 28, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
April 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
April 19, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Annie McGuire as General Counsel
February 28, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
February 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
February 15, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
February 14, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
January 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
January 24, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
January 06, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
December 14, 2021
From
Veracyte, Inc.
Via
Business Wire
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
December 01, 2021
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the...
Via
FinancialNewsMedia
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
November 24, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
November 13, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Third Quarter 2021 Financial Results
November 09, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
November 05, 2021
From
Veracyte, Inc.
Via
Business Wire
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
November 03, 2021
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
November 02, 2021
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.